• news.cision.com/
  • NEL ASA/
  • DiaGenic awarded research grant of NOK 7.8 million for further development of DiaGenics tests for early detection of Alzheimer’s disease
English

DiaGenic awarded research grant of NOK 7.8 million for further development of DiaGenics tests for early detection of Alzheimer’s disease

Report this content

DiaGenic has been granted NOK 7.8 million of the Norwegian Research Council`s BIA funds. The funds will be employed in an industry-oriented research project to improve robustness and reduce costs of procedure in blood based diagnostics of Alzheimer’s disease. The clinical samples will be sourced from DiaGenic’s biobank as well as the HUNT Biosciences biobank.

The grant announcement for the project “Blood microRNAs for the early diagnosis of Alzheimer’s disease” was made public today by the Research Council of Norway and is conditional upon signature by the parties. 

“Norwegian Research Council has in the past contributed with significant funding for DiaGenic’s development of diagnostic tests. This new grant for development of blood based diagnostics for early Alzheimer’s disease represents an important financial contribution", says CEO in DiaGenic, MD PhD Henrik Lund.

Contact:

Henrik Lund, CEO

Telephone: 47 90971219

e-mail: henrik.lund@diagenic.com

About DiaGenic ASA

DiaGenic seeks to create value for patients, partners, and investors by developing innovative and more patient friendly methods for early detection of diseases utilizing DiaGenic’s unique concept. The concept implies that a disease evokes systemic responses in the blood unique for the disease, and which can be measured by using blood samples.

DiaGenic is a world leader in identifying these gene expression signatures in peripheral blood and is focused on the development of biomarkers in the field of Alzheimer’s disease and Parkinson’s disease. DiaGenic’s Alzheimer’s disease development program includes the CE marked diagnostic test ADtect®, for detection of mild to moderate Alzheimer’s disease, and MCItect®which is under development for identifying patients with very early stages of Alzheimer’s disease (prodromal AD).

DiaGenic’s concept is protected through an extensive patent portfolio. DiaGenic promotes its products and services towards leading pharmaceutical, imaging and diagnostic companies. DiaGenic is located in Norway and listed on the Oslo Stock Exchange. For more information please visit: www.diagenic.com

Subscribe